Added to YB: 2026-05-08
Pitch date: 2026-05-06
MDNA.TO [neutral]
Medicenna Therapeutics Corp.
-7.81%
current return
Author Info
Penny Queen focuses on undiscovered value, deep dives, swing trades and special situations. Sign up for the newsletter.
Company Info
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases.
Market Cap
CAD 51.7M
Pitch Price
CAD 0.64
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.85
P/E
-3.91
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Partial Portfolio Update: Three Catalysts, Two Interviews and an Exit - Medicenna Therapeutics Corp.
MDNA.TO (holding update): ASCO TPS poster May 31 w/ Ascierto on NEO-CYT trial (MDNA11+nivo±ipi in Stage III melanoma)—no data yet, but high-profile validation. Real catalysts H2 2026: NEO-CYT interim data, ABILITY-1 update (2L/3L+NSCLC cohorts), FDA end-of-Phase 1 meeting, MDNA113 IND filing. IL-2 space heating via M&A; differentiated CD122/albumin design. Clinical-stage binary risk.
Read full article (2 min)